Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Reuters NewMedia - October 8, 2007
The $26.8 million program will deliver drugs to around 750,000 people in 19 countries, covering their anti-tuberculosis drug needs for the rest of this year and 2008, the Stop TB Partnership, hosted by the WHO, and the UNITAID initiative said in a joint statement.
The initiative will provide drugs to countries expanding their TB control efforts and that have been promised support from the Global Fund to Fight AIDS, Tuberculosis and Malaria or another donor, but do not yet have the funds.
A six-month course of treatment for TB for someone of average weight costs $20.
TB and AIDS are the main health threats in Africa and are closely linked, with victims of one often vulnerable to the other.
Worldwide, 8.8 million new cases of TB and 1.6 million deaths from it occur each year. If left untreated, TB can develop into drug-resistant strains.
"This is the first line to prevent the creation of drug resistance," Marcos Espinal, executive secretary of the Stop TB Partnership, told a news conference.
The project is restricted to anti-TB treatments suitable for people whose TB is not resistant to standard therapies. It will also allow the creation of a stockpile of anti-TB drugs.
The drugs are sourced from four generics manufacturers in India, said Robert Matiru, operations manager of the Stop TB Partnership's Global Drugs Facility.
They are Lupin, Cadila, Sandoz India and Svizera Europe, he said.
The project will provide first-line TB drugs to Bangladesh, Bosnia, Burkina Faso, Cameroon, Cote d'Ivoire, Guinea, Iraq, Kenya, Madagascar, Mali, Mozambique, Myanmar, Niger, Nigeria, Rwanda, Tajikistan, Gambia, Togo and Uganda.
071008
RE071009
Copyright © 2007 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .